Prostate brachytherapy has come of age: a review of the technique and results

[1]  D. Gillatt,et al.  Prevalence and Impact of Incontinence and Impotence following Total Prostatectomy Assessed Anonymously by the ICS-Male Questionnaire , 1998, European Urology.

[2]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[3]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[4]  J. Blasko,et al.  Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. , 2000, Seminars in urologic oncology.

[5]  W. Lee,et al.  Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. , 2000, International journal of radiation oncology, biology, physics.

[6]  L. Potters,et al.  Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. , 1999, The cancer journal from Scientific American.

[7]  A. Porter,et al.  Quality of life after permanent prostate implant. , 1997, Seminars in surgical oncology.

[8]  A. Dicker,et al.  Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry. , 2000, Seminars in urologic oncology.

[9]  D. Gladstone,et al.  Prostate seed implant quality assessment using MR and CT image fusion. , 1999, International journal of radiation oncology, biology, physics.

[10]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[11]  Duchesne Gm,et al.  What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. , 1999 .

[12]  H. Ragde,et al.  Ten‐year disease free survival after transperineal sonography‐guided iodine‐125 brachytherapy with or without 45‐gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma , 1999, Cancer.

[13]  R. Stock,et al.  The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, Seminars in surgical oncology.

[14]  Michael J. Zelefsky,et al.  Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .

[15]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[16]  M. Litwin,et al.  Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. , 2000, The Journal of urology.

[17]  D. Brachman,et al.  Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. , 2000, International journal of radiation oncology, biology, physics.

[18]  J. Payne,et al.  Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. , 1995, The Journal of urology.

[19]  P. Unger,et al.  Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma , 1996, Cancer.

[20]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[21]  D. Spelbring,et al.  The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[22]  J. Forman,et al.  Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. , 1995, Cancer investigation.

[23]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[24]  A. Shanberg,et al.  Temporary iridium‐192 implant in the management of carcinoma of the prostate , 1992, Cancer.

[25]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  The case for external beam treatment of early-stage prostate cancer. , 2000, Urology.

[27]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[28]  W. Catalona,et al.  Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer. , 1999, The Journal of urology.

[29]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[30]  M. Zelefsky,et al.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.

[31]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[32]  W. Butler,et al.  Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.

[33]  Haakon Ragde,et al.  Modern prostate brachytherapy , 2000 .

[34]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[35]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[36]  J M Collins,et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. , 1998, International journal of radiation oncology, biology, physics.

[37]  J. Payne,et al.  Original Articles: Prostate Cancer , 1995 .

[38]  A new device to stabilize templates for transperineal I-125 implants. , 1991, International journal of radiation oncology, biology, physics.

[39]  R. Stock,et al.  Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. , 1998, Radiation oncology investigations.

[40]  J. Usenius,et al.  Adenine phosphoribosyltransferase deficiency: 2,8-dihydroxyadenine urolithiasis in a 48-year-old woman. , 1988, British journal of urology.

[41]  J. Blasko,et al.  Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[42]  J. Roy,et al.  Short-term freedom from disease progression after I-125 prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[43]  W Cavanagh,et al.  The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  S. Kalnicki,et al.  Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation. , 2000, International journal of radiation oncology, biology, physics.

[45]  L. Potters,et al.  Isotope selection for patients undergoing prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[46]  A. Garden,et al.  Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. , 1990, International journal of radiation oncology, biology, physics.

[47]  L. Potters,et al.  Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[48]  C. Ling.  Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. , 1992, International journal of radiation oncology, biology, physics.

[49]  S. Stokes,et al.  Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. , 2000, International journal of radiation oncology, biology, physics.

[50]  H. Holm,et al.  Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. , 1983, The Journal of urology.

[51]  K. Wallner,et al.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[52]  H. Ragde,et al.  Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. , 2000, Cancer.

[53]  W. Whitmore,et al.  Retropubic implantation to iodine 125 in the treatment of prostatic cancer. , 1972, The Journal of urology.

[54]  P. Walsh.  Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. , 2000, The Journal of urology.

[55]  J. Payne,et al.  Improved technique for prostate seed implantation: combined ultrasound and fluoroscopic guidance , 1992 .

[56]  H. Ragde,et al.  Modern prostate brachytherapy , 2000 .

[57]  W. Lee,et al.  Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. , 1999, The Journal of urology.

[58]  R. Stock,et al.  Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. , 2001, The Journal of urology.

[59]  A. Moss,et al.  Value of computed tomography in interstitial 125I brachytherapy of prostatic carcinoma. , 1983, Radiology.

[60]  S. P. Mitchell,et al.  Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. , 2001, The Journal of urology.

[61]  R. Dale.  Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. , 1989, The British journal of radiology.

[62]  A. Fortin,et al.  Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[63]  L L Anderson,et al.  Spacing nomograph for interstitial implants of 125I seeds. , 1976, Medical physics.

[64]  D. Theodorescu,et al.  Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. , 2000, Urology.

[65]  W Cavanagh,et al.  Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. , 1997, Seminars in surgical oncology.

[66]  W Cavanagh,et al.  Palladium-103 brachytherapy for prostate carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[67]  J. Blasko,et al.  Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[68]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[69]  Blasko,et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[70]  R. Stock,et al.  Prostate brachytherapy: treatment strategies. , 1999, The Journal of urology.

[71]  K. C. Lee,et al.  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. , 1999, Cancer.

[72]  W. Butler,et al.  Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. , 1999, Urology.

[73]  M. Litwin,et al.  Quality of life outcomes after brachytherapy for early stage prostate cancer. , 2000, The Journal of urology.

[74]  D. Dearnaley,et al.  Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. , 1992, British journal of urology.

[75]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.

[76]  A. Hanlon,et al.  Dose selection for prostate cancer patients based on dose comparison and dose response studies. , 2000, International journal of radiation oncology, biology, physics.

[77]  J Roy,et al.  Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.

[78]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.